Table 6 Key Findings for the influence of designated Strategic Health Authority/Health Board of treatment and access to chemotherapy

Cartman ‘02 [35]

The proportion of patients having chemotherapy was 9.5 % (range 5 % to 12.9 %)

Adjusted analysis performed for survival regression analysis only

Not performed

Jack ‘03 [37]

Median % and range of chemo-therapy by health authority: chemo-therapy alone: 4 %, range 3-9 %, any chemo-therapy median 8 %, range 4-17 %.

Odds of chemotherapy if first hospital visited was a radiotherapy centre: OR 1.38 (1.06 to 1.80).

P = 0.018

Paterson ‘13 [42]

Unadjusted OR not given

Health board A, OR 1.00 (0.89, 1.38) (of any chemotherapy), Health board B OR 1.11 (0.89 to 1.38) P 0.36, Health board C OR 1.07, (0.91 to 1.25)

Health Board B 0.36

Health Board C 0.42

Stephens ‘12 [33]

From figure.

Not performed

Not performed

Everolimus 0.2 to 2.1 mg per head pre CDF across five SHAs reduced to 0.55 to 1.45 post-CDF; Lapatinib 0.05 to 2.0 pre-CDF and 0.70 to 1.25 after; Sorafenib 0.08 to 2.5 pre-CDF and 0.45 to 1.3 after; Bevacizumab and Cetuximab 0.25 to 2.1 pre and 0.45 to 2.0 post-CDF.